Screener
Vor Biopharma VOR EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Vor Biopharma in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Vor Biopharma’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 8:31 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-220689
| (in thousands, except share and per share amounts) | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Change in fair value of warrant liabilities | (188,360) | — |
| Total other (expense) income | (184,425) | 805 |
| Net loss | $(219,585) | $(32,486) |
| Net loss per share attributable to common stockholders, basic and diluted(1) | $(5.11) | $(5.21) |
| Weighted-average common shares outstanding, basic and diluted(1) | 43,011,544 | 6,241,207 |
| Other comprehensive income (loss): | ||
| Unrealized (loss) gain on available for sale marketable securities | (747) | 1 |
| Total other comprehensive (loss) income: | (747) | 1 |
Item 1. Financial Statements (Unaudited).
FAQ
- What is Vor Biopharma's EPS (diluted)?
- Vor Biopharma (VOR) reported EPS (diluted) of -$5.11 in Q1 2026.
- How has Vor Biopharma's EPS (diluted) changed year-over-year?
- Vor Biopharma's EPS (diluted) increased by 1.9% year-over-year, from -$5.21 to -$5.11.
- What is the long-term trend for Vor Biopharma's EPS (diluted)?
- Over 3 years (2021 to 2024), Vor Biopharma's EPS (diluted) has grown at a 101.9% compound annual growth rate (CAGR), from -$2.15 to -$17.69.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Vor Biopharma's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude